Clerkenwell Health closed its initial round of funding to launch a clinical research organisation with key hires and a partnership with Manchester University The launch of Clerkenwell Health further positions the UK as an attractive destination for international psychedelic drug developers looking to conduct trials A Memorandum of Understanding (MOU) has been signed with Manchester University…


Previous articleField Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results
Next articlePTSF65 – Navigating Psychedelics for Clinicians and Therapists, and Nitrous Oxide for Depression